HYPERSEN
16.11.2022 11:49:34 CET | Business Wire | Press release
As a leader in chromatic confocal technology, Hypersen is pleased to release a Coaxial 3D Line Confocal Sensor (HPS-LCX1000) for the global measurement & inspection market. This sensor offers an effective and high-precision (0.1µm) 3D inspection solution to the measurement and defects detection problems in the fields of semiconductors, consumer electronics, new energy, metal, automobile, and aviation.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20221115006199/en/
Hypersen releases a coaxial 3D line confocal sensor HPS-LCX1000 to tackle the difficulties in measurement and inspection of semiconductor wafer/chip, LED/OLED display, electronic components, metal, automotive and aerospace parts. It solves the shadowing problem when measuring targets with holes, steep slopes, and protruding components. (Photo: Business Wire)
Compared to current line confocal sensors, HPS-LCX1000 excels in its lateral resolution (1.1µm) and coaxial structure. Coaxial design means the incident and reflected rays overlap. Therefore, it solves the shadowing problem when measuring targets with holes, steep slopes, and protruding components.
In addition, it has the following advantages:
- High adaptability to various materials, especially transparent and highly reflective ones, mirrored surfaces, and even liquid
- Robust capability to measure complex geometric shapes
- Max. surface slope on mirror: ±45°
- Generate 2D image and 3D point cloud data by one scan
- Axial precision: 0.1µm
- Point density: 2,048 points/profile
- High scan speed: up to 35,000 lines/sec.
Separated sensor head and controller design greatly reduces the measurement error caused by heat generation of the sensor. Besides that, a 40G optical fiber enables low-latency data transmission between the sensor head and the controller. What’s more, the controller is equipped with an 8-core 64-bit CPU, high-speed FPGA and an AI accelerator. With integrated high efficient AI algorithm, HPS-LCX1000 reaches a scanning speed of 35,000 lines/sec. and enables real-time 3D point cloud data output.
What HPS-LCX1000 can do:
- 3D topography and dimension measurement
- Surface defects detection
- Curved surface measurement
- Displacement and roughness measurement
- Gap and flush measurement
- Thickness measurement of multi-layer transparent materials
Test engineers can find this sensor very helpful when conducting the following tasks:
- Wafer and PCB bumps 3D inspection
- Die defects detection
- IC chip pin 3D inspection
- Wire bonding defects detection
- Highly angled LED/OLED display profile measurement
- Smart watch components measurement
- Gluing effects inspection
- Automotive and aerospace components appearance inspection
About Hypersen Technologies:
Established in 2015, Hypersen manufactures and sells high-end optical and force torque sensors. As an innovative company in high-precision measurement field, Hypersen provides: 3D optical profilometer, 3D line confocal sensor, chromatic confocal sensor, high speed industrial camera, 3D LiDAR and 6-axis force torque sensor.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221115006199/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Merz Therapeutics Presents New Phase 2 PaiNT Data in Peripheral Neuropathic Pain at IASP 202626.10.2026 08:00:00 CET | Press release
Clinical and preclinical presentations reflect the company’s ongoing exploration of peripheral neuropathic pain Merz Therapeutics, a leading player in neurology-focused specialty pharma, today announced the presentation of new clinical and translational research in peripheral neuropathic pain (PNP) at the International Association for the Study of Pain (IASP) 2026 World Congress in Bangkok, Thailand, taking place from 26 to 30 October. The research spans new Phase 2 findings on incobotulinumtoxinA in postherpetic neuralgia (PHN) and post-surgical/post-traumatic neuropathic pain (PS/PTNP), as well as preclinical studies exploring potential biological mechanisms involved in effects of incobotulinumtoxinA on PNP models, highlighting Merz Therapeutics’ growing presence in neuropathic pain. In the PHN population of the Phase 2 PaiNT trial, results over 20 weeks favored incobotulinumtoxinA versus placebo treatment. In an exploratory analysis of average daily pain (ADP) intensity, the greates
Andersen Consulting tilføjer samarbejdsfirmaet TechSparq25.10.2026 06:09:00 CET | Pressemeddelelse
Andersen Consulting udvider sine kompetencer inden for teknologi og forretningstransformation gennem en samarbejdsaftale med TechSparq, en amerikansk virksomhed, der kombinerer strategi, commerce engineering og ai med praktisk implementering. TechSparq er et digitalt konsulenthus, der tilbyder strategi- og rådgivningstjenester, commerce engineering samt tjenester inden for ai og agentbaseret handel til virksomheder inden for detailhandel og forbrugsgoder, luksus og mode samt e-handel og direkte salg til forbrugere. Virksomheden har hovedkontor i Oregon og kombinerer strategisk planlægning med praktisk implementering for at hjælpe kunderne med at udvikle deres digitale initiativer, kundeoplevelse og driftsmodeller. "Vi etablerede vores virksomhed for at bygge bro mellem dem, der udvikler strategien, og dem, der har ansvaret for at føre den ud i livet," udtalte Dedrick Boyd, stifter af og administrerende direktør for TechSparq. "Vores samarbejde med Andersen Consulting giver os mulighed
BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 10:15:00 CEST | Press release
Potential first-in-class GPC3 x 4-1BB bispecific achieves a 36% confirmed response rate at Phase 3 dose and favorable safety profile in heavily pretreated liver cancerBrain-penetrant PRMT5 inhibitor shows promising antitumor and CNS activity in the largest publicly shared MTAP-deficient datasetFirst clinical data of CEA-targeting ADC demonstrates encouraging and sustained responses in CEAhigh NSCLC BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to dise
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press release
- Vertex is on track for the U.S. FDA Prescription Drug User Fee Act (PDUFA) date of November 30 for potential accelerated approval of povetacicept –- Data published in NEJM and presented at ASN highlight povetacicept’s unique trifecta of efficacy, favorable safety, and the simplicity of dosing at-home every 4 weeks with a low-volume autoinjector –- Data presented at ASN include a qualitative study examining patient perspectives on current and emerging IgAN therapies, showing that 96% of participants preferred an autoinjector over a prefilled syringe, and 80% of participants preferred dosing every 4 weeks versus weekly dosing - - New clinical studies of povetacicept underway including a study evaluating patient experience on povetacicept administered via autoinjector - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Soc
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release
New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom